1 Research participants' perception of ethical issues in stroke genomics and neurobiobanking

2 research in Africa

3 Authors

Avodele Jegede¹, Olubukola Balogun¹, Olorunyomi Felix Olorunsogbon^{2,3} Michelle Nichols⁴ 4 Joshua Akinyemi⁵, Carolyn Jenkins⁴, Mayowa Ogunronbi², Arti Singh⁶, Reginald Obiako⁷, 5 Kolawole Wahab⁸, Abiodun Bello⁸ Albert Akpalu⁹, Fred S. Sarfo¹⁰, Lukman F. Owolabi¹¹, 6 Babatunde Ojebuyi¹², Muyiwa Adigun¹³, Dorcas Olujobi², Rabiu Musbahu¹¹, Musibau 7 Titiloye³, Ibukun Afolami¹⁴, Benedict Calys-Tagoe⁹, Ezinne Uvere¹⁵, Ruth Laryea⁹, Adekunle 8 9 Fakunle¹⁵, Osi Adeleye¹⁶, Deborah Adesina¹⁶, Nathaniel Mensah¹⁰, Wisdom Oguike⁷, Nathaniel Coleman⁹, Sunday Adeniyi⁸, Lanre Omotoso⁸, Shadrack Asibey¹⁰, Lois Melikam⁷, Jibril Yusuf¹¹, 10 Abdullateef Gbenga⁷, Aliyu Mande¹¹, Muhammed Uthman⁸, Rajesh N. Kalaria^{2,17}, Mayowa 11 Owolabi^{15,18}, Bruce Ovbiagele¹⁹, Oyedunni Arulogun², Rufus O. Akinyemi^{2,15,18*} 12 13 Affiliations ¹Department of Sociology, Faculty of the Social Sciences, University of Ibadan, Nigeria 14 15 ²Neuroscience and Ageing Research Unit, Institute for Advanced Medical Research and Training, 16 College of Medicine, University of Ibadan, Nigeria ³Department of Health Promotion and Education, Faculty of Public Health, University of Ibadan, 17 18 Nigeria 19 ⁴College of Nursing, Medical University of South Carolina, Charleston, SC, USA 20 ⁵Department of Epidemiology and Medical Statistics, College of Medicine, University of Ibadan, 21 Nigeria

- ⁶School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi,
- 23 Ghana
- ²⁴ ⁷Neurology Unit, Department of Medicine, Ahmadu Bello University Teaching Hospital, Shika,
- 25 Zaria, Nigeria
- ²⁶ ⁸Neurology Unit, Department of Medicine, University of Ilorin Teaching Hospital, University of
- 27 Ilorin, Nigeria
- ⁹University of Ghana Medical School, College of Health Sciences, Accra, Ghana
- 29 ¹⁰Neurology Unit, Department of Medicine, Kwame Nkrumah University of Science and
- 30 Technology, Kumasi, Ghana
- ¹¹Neurology Unit, Department of Medicine, Bayero University/Aminu Kano Teaching Hospital,
 Kano, Nigeria
- ¹²Department of Communication and Language Arts, Faculty of Arts, University of Ibadan,
 Nigeria
- ¹³Department of Public Law, Faculty of Law, University of Ibadan, Ibadan, Nigeria.

¹⁴Department of Human Nutrition and Dietetics, College of Medicine, University of Ibadan,
Nigeria.

- ¹⁵Department of Medicine, College of Medicine, University of Ibadan, Nigeria
- ³⁹ ¹⁶Neurology Unit, Department of Medicine, Federal Medical Centre, Abeokuta, Nigeria
- 40 ¹⁷Neurovascular Research Group, Institute of Neuroscience, Newcastle University, Newcastle
- 41 upon Tyne, United Kingdom

42	¹⁸ Centre for Genomic and Precision Medicine, College of Medicine, University of Ibadan, Nigeria
43	¹⁹ School of Medicine, University of California, San Francisco, CA, USA
44	*Corresponding Author: roakinyemi@yahoo.com (ROA)
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	

64 Abstract

65 Background: There is a growing interest in stroke genomics and neurobiobanking research in Africa. These raise several ethical issues, such as consent, re-use, data sharing, storage, and 66 67 incidental result of biological samples. Despite the availability of ethical guidelines developed for 68 research in Africa, there is paucity of information on how the research participants' perspectives could guide the research community on ethical issues in stroke genomics and neurobiobanking 69 70 research. To explore African research participants' perspectives on these issues, a study was conducted at existing Stroke Investigation Research and Education Network (SIREN) sites in 71 72 Nigeria and Ghana.

Method: Using an exploratory design, twenty-eight Focus Group Discussions (FGDs) sessions were conducted with stroke survivors (n=7), caregivers(n=7), stroke - free controls(n=7), and Community Advisory Board members(n=7). Data were collected using an interview guide. Interviews were conducted in English and indigenous languages of the community, audio recorded, and transcribed verbatim. Data were analyzed using NVivo (March, 2020) Software.

Result: Results revealed that stroke genomics and neurobiobanking research in Africa require researchers' direct attention to ethical issues. Concerns were raised about understanding, disclosure and absence of coercion as components of true autonomous decision making in research participation. Participants argued that the risk and benefits attached to participation should be disclosed at the time of recruitment. Fears around data sharing were voiced as adherence to the principle of privacy and confidentiality were of paramount importance to participants. The preference was to receive the results of incidental findings with no stigma attached from society.

85 Conclusion: Research participants' perspectives are a vital aspect of community engagement in 86 stroke genomics and neurobiobanking research. Findings from this study suggest that research

87 participants are interested in these fields of research in Africa if their concerns about ethical issues

are appropriately addressed within the research framework.

89 Keyword: Perception, ethical issues, neurobiobanking, stroke genomics, Africa

90

91 Introduction

As part of the efforts targeted towards combating the increasing prevalence and incidence of stroke and other cerebrovascular disorders (CVDs) in low- and middle-income countries (LMICs), especially in sub-Saharan Africa, genomics and neurobiobanking-based studies are on the increase. However, despite the scientific advancements, there exist challenges relating to ethical, legal, and social issues (ELSI). Hence, it is important to identify and develop strategies for addressing these challenges in the region.

For about a decade, the Human Heredity and Health in Africa (H3Africa) consortium has engaged 98 99 in research on the African continent to generate data and samples that could be used to improve 100 global health [1, 2]. In essence, they have developed numerous guiding documents on ethics, 101 informed consent, governance, data sharing, and community engagement[3]. The African 102 Neurobiobank for Precision Stroke Medicine (ELSI) project within the H3Africa consortium is a stroke genomic and neurobiobanking project across seven cities in Africa with the goal of 103 104 identifying, examining, and developing novel approaches to address ELSI of biobanking and 105 stroke genomic research in sub-Saharan Africa[4]

106 Stroke genomics research raises several ethical questions and challenges [5], such as informed 107 consent (who can give informed consent, type/nature of consent, what information should be 108 contained in consent forms), sample ownership and management, sample sharing and storage, data

storage and sharing, and role of regulatory committees are some of the ethical issues identified andbroadly discussed in the literature[6].

Neurobiobanks are organized repositories for collection, storage, sharing and reuse of brain tissues, 111 112 whole brain specimens and associated data for neurological research purposes [7]. These samples 113 and data are used for a broad range of applied research activities in the development of tools 114 tailored towards the prevention, diagnosis and treatment of diseases also known as precision medicine (PM). The samples and data are stored to be used for further research either in the 115 countries of origin or other countries[7]. The field of neurobiobanking is growing in Africa with 116 117 few studies already being conducted to understand the perspectives and willingness towards brain donation and brain banking among Africans[4, 8]. In addition, organized brain bank is being 118 developed to accrue and store neural tissues for future research in neurology and psychiatry[9]. 119

Genomics data deals with highly sensitive personal information which could significantly impact the lives of participants and their families. There is a need to consider ELSI in practice as there is still a dearth of literature about the consistent definition of key factors that constitute the ELSI variables in genomic research [10].

Though gaps exist in literature about what constitute and are defined as ethical criteria, most of 124 these hinge on bioethical principles of beneficence, non-maleficence and autonomy, including 125 those criteria that refer to human rights and dignity[10]. For reflection on ethical issues, empirical 126 studies exploring research participants' views and perceptions provide a good starting point to 127 128 understanding stroke genomic and neurobiobanking research. Due to the complexity of the concepts and the vast cultural and geographical diversities in a multi-ethnic society, it is necessary 129 130 to explore views from multicultural and diverse participants, including stroke survivors, 131 caregivers, stroke free controls and Community Advisory Board (CAB) members.

In this study, we adopted Beauchamp's and Childress' four principles of beneficence, nonmaleficence, autonomy and justice[11] for discussion of ethical issues in stroke genomic and neurobiobanking research. Autonomy is based on the principle of respect for persons to make their own choice or decision. The principle of beneficence is contained in the Hippocratic Oath which guides medical practice and is hinged on the principle of doing good or what will enhance patients' interest. The ethical principle of non-maleficence requires that harm should be avoided to participants[12]

139

140 Method

141 Setting

The study was conducted in seven cities, five in Nigeria (Abeokuta, Ibadan, Ilorin, Kano and Zaria)
and two in Ghana (Accra and Kumasi), as an integral part of an ongoing study [4].

144 Study design

145 The study design was exploratory and employed Focus Group Discussions (FGDs) (S1 File) to 146 investigate participants' perception of ethical issues in stroke genomics and neurobiobanking 147 research.

148 **Study population**

The study population consisted of purposively selected stroke survivors, caregivers, stroke - free controls and Community Advisory Board (CAB) members between the ages of 18-85 involved in the SIREN study (Table 1) from seven sites in the established SIREN communities in Southern (Abeokuta and Ibadan), Central (Ilorin), and Northern (Kano and Zaria) Nigeria and Southern (Accra) and Central (Kumasi) Ghana[4]

154 Instrument

The FGD guide (S1 File) was developed from peer-reviewed literature relating to ELSI of neurobiobanking and stroke genomics, as well as lay literature in study communities/sites. The FGD guide explored issues around informed consent, data sharing, sample storage and reuse, feedback of research result and incidental findings, bio-right, governance, and regulation[4]

159

160 **Ethical consideration**

161 All the seven sites obtained ethical approval from their institutional ethics review committee before 162 the commencement of the study. University of Ibadan, Oyo State, Nigeria (UI/EC/18/0641); 163 Federal Medical Centre, Abeokuta, Ogun State, Nigeria (FMCA/470/HREC/04/2019/01) Murtala 164 Muhammad Specialist Hospital, Kano State, Nigeria (MOH/OFF/797/TI/1264); Ahmadu Bello 165 University Teaching Hospital, Zaria, Kaduna State, Nigeria (ABUTHZ/HREC/E25/2018); University of Ilorin Teaching Hospital, Kwara State, Nigeria (UITH/CAT/189/19/007); 166 University of Ghana College of Health Sciences, Accra, Ghana (EPRC/FEB/2021); Kwame 167 168 Nkrumah University of Science and Technology, Kumasi, Ghana (CHRPE/AP/262/20). Written informed consent was obtained from each FGD participant. Participants were informed in detail 169 about the study. Participation in this study was voluntary. The study participants were informed 170 171 that they could withdraw from the study at any stage without any consequences to their benefiting from the outcome of the study, if any. To ensure confidentiality of study participants' identity, 172 173 numeric codes were allotted to each participant and only researchers had access to the data. Identifiers were removed from the transcripts. 174

175

176 Data collection procedure, management, and analysis

A total of twenty- eight FGD sessions were conducted across all the seven sites between 26th June 177 2019 and Feb 2020, and each session included between six and ten participants to ensure 178 179 meaningful but actively guided discussions. CAB members were first briefed about the project 180 during CAB meetings at each site and subsequently received updates at all CAB meetings. Other 181 participants were approached and briefed by the study site coordinators about the study objectives. Participants were enrolled following informed consent. FGD sessions were held separately with 182 183 each of the groups (stroke survivors, stroke caregivers, stroke-free control, and CAB members) in their respective sites. An interactive information sharing approach as a technique was adopted for 184 185 this study, which involved participants providing information about stroke genomic and 186 neurobiobanking research.

FGD sessions were conducted by a team comprising study sites coordinator and research assistants with experience in FGDs and qualitative research methods. Preceding the commencement of the FGDs, the research teams were trained on the protocol for data collection for this study. A pilot of the FGDs guide was carried out and revised before the actual data collection. The FGD sessions lasted on the average between 40-60 minutes.

All discussions were audio-recorded with the verbal consent of participants. The audio recordings were later transcribed verbatim and uploaded on REDCap, a secure data storage site. Transcripts were imported into NVivo (March 2020) software. The transcripts were reviewed and coded by three of the authors following the thematic framework for coding. Codes were generated in themes, inductively and deductively, both from literature and data [13]. The framework approach involving five stages were used which comprises:1) familiarization 2) identification of thematic framework 3) indexing 4) charting and 5) mapping and interpretation of data for data analysis.

199

200 **Results**

- 201 A total of two hundred and thirteen persons (n =213) participated in the FGDs as presented in
- 202 Table 1. The five themes identified from within the data were related to Beauchamp and Childress'
- 203 principles of biomedical ethics[11].
- 204 Table 1. Focus group demographics

Study participants	Age range (years)	Males	Females	Total
Stroke survivor	22-80	27	22	49
Stroke free controls	22-65	31	18	49
Stroke caregiver	17-74	29	27	56
Community Advisory Board	27-82	45	14	59
Total	17-82	132	81	213

205

The analysis focused on exploring ethically relevant themes from research participants' views, although the results are organized and presented according to Beauchamp and Childress' principles of biomedical ethics[11]. Extracted text from participants' perspectives were assigned to different themes and discussed iteratively.

- 212
- 213
- 214
- 215

216

8	Bioethical principle	Themes
9	Autonomy	Understanding of research purpose
0		Disclosure of details of the research process
1		Coercion
		Inducement
	Beneficence	Individual Outcomes
		Knowledge of treatment
		Diagnosis of stroke disorder
	Non-maleficence	Privacy and confidentiality
		Data security
		Stigmatization

217 **Table 2: Bioethical principles and themes**

222 Autonomy

Autonomy was explored regarding how participants viewed the informed consent process towards 223 224 empowering decision making. Specifically, this pertains to how individuals voluntarily decide to 225 participate in stroke genomic and neurobiobanking research. Majority of study participants 226 indicated that there is the need to empower people with adequate information through the consent 227 process by the researchers prior to participation to be able to express themselves voluntarily 228 (Patient right). Participants expressed that for autonomous decision making (right to participate 229 without coercion), an understanding of the purpose of the research, full disclosure of the research 230 process and information about the study are important before consent.

231 Understanding of research purpose

232	Participants in this study indicated that a detailed explanation of the purpose of the research
233	including the use of bio-samples should be expressly communicated before obtaining consent and
234	participant understanding is crucial to decision making. Participants emphasized comprehensive
235	understanding to prevent withdrawal. A respondent said:
236	What I understandis before I join you in doing whatever you bring to me, you
237	need to share information about what you want to do and make sure I understand
238	it, get my feedback to say that I understand it. It is then I can agree if I can continue
239	with you or not. (Stroke - free control, Abeokuta)
240	A stroke caregiver respondent clarified that 'the individual must be properly counseled about
241	the purpose of the research, and she/he must understand it (Stroke caregiver, Zaria).
242	CAB members across sites corroborated this view as indicated by a participant,
243	"What I know is that everything someone does, there is the need to brief her/him.
244	Someone needs to be educated about it. If someone understands and accepts to do
245	itthen she/he can sign for it" (CAB member, Kumasi).
246	The central hallmark of the participants' views is that participants' empowerment will enable
247	research participants make informed voluntary decisions. For them, once participants have
248	adequate knowledge of the study it will be easy to make an informed decision.
249	

250 **Disclosure of details of research processes**

251 Participants expressed the need to be provided with detailed information about the research 252 processes including the risk and benefit associated with the use of samples obtained through the 253 research.

254	Permission given with the full knowledge of the implications of their actions in
255	terms of the side effects associated with the exact procedure that will be done on
256	them, the products that will be obtained from them, how they will be obtained, and
257	the consequences of it, if any (Stroke caregiver, Zaria)
258	This view was corroborated by the CAB participants saying that full disclosure of
259	information about the research to be carried out for which participants would be recruited
260	is important. According to a participant:
261	There must be full disclosure and the complete information must be provided
262	regarding the purpose for this research (CAB, Zaria).
263	This view was corroborated by the stroke survivor group according to one of them saying:
264	It is telling people all about the research - the good, the bad, and the ugly part of
265	the research. Thereby participants are making an informed decision to be part of
266	the studies. (Stroke survivor, Zaria)
267	With respect to ethical concerns about neurobiobanking research, most respondents were in full
268	support of sample usage, storage, and data sharing provided study participants are duly informed
269	So you have to inform the person that sample will be stored for future use because
270	you cannot just take the sample and use it without informing the person (Stroke
271	Free control, Accra).

272 Coercion

273	Participants were of the view that consent should be sought without coercion. They argued that
274	participants should have a good understanding of the reasons they should participate in the
275	research. For instance, a participant said:
276	Consent that is given out of knowledge, for the fact that you know, not that you were
277	compelled, or you are forced, or you are coercedit means you have been told what
278	it entails. (Abeokuta, CAB).
279	
280	A stroke - free control participant emphasized the need for voluntariness (out of a free will) saying:
281	that everything that you are doing (participation) is out of your own free will, you
282	know nobody is forcing you to do it, every role you are to play, you are playing it
283	freely and you are not doing it under duress. (Stroke - free control, Abeokuta).

284 Inducement

Participants emphasized that research participants should not be made to participate in research by giving or promising them what would make them lose their senses in making an irrational decision. For them, consent must be given freely without undue inducement. Adequate knowledge of the research activities was considered important for avoiding undue inducement. According to a participant:

290 You know what you are doing, you are not just giving the consent out of any 291 inducement, it is done voluntarily, it is done by knowledge, it is done with full 292 information at your disposal (CAB, Abeokuta).

293 **Beneficence**

294	With regards to the benefits of participating and sharing genetic information, participants across
295	sites hold positive and inviting views towards stroke genomic research. The views are categorized
296	into three themes: Individual outcomes, knowledge of treatment of stroke, and diagnosis of stroke.
297	This will guide effective and informed participation in research.
298	Individual outcomes
299	Participants revealed that individual outcomes (benefits) as important ingredients in research
300	participation. This view is rooted in the idea that individual outcomes of participating in research
301	provide benefits to the community
302	You can share with others; we too can gain from their research. For example,
303	they can do research we have not done, we can benefit from them. We too can-do
304	research and they will benefit from us (Stroke survivor, Ilorin).
305	
306	However, participants echoed the need to be informed about the risk and potential benefits of the
307	study before consenting to participate indicated that the benefits are outlined and if there are
308	any risk too you are told (CAB, Accra).
309	
310	This view was corroborated by the stroke - free control group in Ibadan saying:
311	'The person must know about what he wants to get into and the benefits he will
312	derive from it, the importance of the research, what he is going to gain from it
313	before he can agree or disagree'. (Stroke -free control, Ibadan).
314	
315	Most of the participants corroborated the fact that participants benefit from research outcomes and
316	individuals can show reciprocity by contributing to research for the benefit of humanity.

317	People have volunteered for research in the past that resulted in knowledge that is
318	beneficial to my health so I would like to contribute to humanity (Stroke Free
319	Control, Ilorin).
320	
321	Another potential benefit was expressed by a stroke survivor:
322	It is good, research helps to inform and make people and government aware of the
323	appropriate medications for certain types of diseases. (Stroke survivor, Kano).
324	Participants' perceptions of sample use for neurobiobanking research were positive as they posited
325	the benefits to the society as stated by a stroke caregiver thus"it is good because it makes
326	diseases to reduce in our environment and anything that will reduce illnesses and diseases is good
327	for our society. (Stroke caregiver, Abeokuta). For the future advancement of genomic science 'It
328	is good because you have something to fall back to when you want to do other genetic research
329	(Stroke survivor, Zaria). As well as benefits to humanity 'well, I think it a good thing I'm positively
330	disposed to it, because the blood sample been kept is going to be used for research purposes that
331	will benefit humanity so I'm positively disposed to it (Stroke - free control, Abeokuta).
332	
333	
334	Discovery of treatment of stroke
335	Most of the participants across the study sites were in support of sharing data from stroke genomic

336 research. They explained that the outcome of the research done with their samples will increase

337 medical knowledge and practice in the treatment of stroke.

338 'There is nothing wrong in that because it is the research some people do that gives
339 us the knowledge of how to treat such diseases. So, if they do our own too and find

340	out the causes of our disease and how the disease can be treated'. (Stroke
341	survivor, Abeokuta).
342	
343	Similarly, a stroke caregiver corroborated the view saying:
344	When you share datait will serve as a standard for other health officials to know
345	how to go about it when someone has the disease and then you can care for people
346	well'. (Stroke caregiver, Accra).
347	
348	The Stroke survivor group agreed with this opinion as indicated by one of them who said:
349	It will increase the knowledge of the researchers and the providers (Stroke survivor,
350	Kano).
351	
352	Similarly, the Stroke caregiver group corroborated the views on the advantages of data sharing
353	citing how it can improve the knowledge of healthcare providers and increase expertise in stroke
354	genomic research. A respondent said:
355	'Sharing of data and other findings concerning participants is very good, it is
356	through that the health providers updates their knowledge and skills to treat
357	patients'. (Stroke caregiver, Kano).
358	
359	Participants also expressed the opinion that storage of bio-samples for research will enhance the
360	advancement of knowledge about diseases and new innovations for treatments.

361	Storage of blood sample or fraction is very good, it is through those future
362	investigations or research are conducted to know about the diseases and the new
363	innovations on treatments and others (Stroke caregiver, Kano).

364 **Diagnosis of stroke genetic disorders**

365 Participants were unanimous that research could advance the process of establishing the diagnoses

366 of stroke genetic disorders as well as finding new treatments. A participant said:

367 And the biobanking that you mentioned, I think it is very purposeful and if it is

368 banked, the purpose of the banking is to ensure that you get the information so let's

369 say you have stroke or the sickness when your blood sample is banked, it helps to

370 *do more ... So then you can also know the severity of the illness)* (Stroke survivor,

371 Accra).

372 Non-maleficence

There was a consensus among participants across the study sites about the use and sharing of data

as well as the return of results. Several ethical concerns on conditions of use, data sharing, and
 return of result/incidental findings were emphasized by the participants.

376

377 **Privacy and confidentiality**

378 Participants' echoed support for sharing of genetic information, if only identity will be protected.

- 379 ... *I* don't see anything wrong with that if it will not involve mentioning our names
- 380 (Stroke survivor Abeokuta).
- Well, I don't have any reservation about it and such information can be shared but
 about that as well will it be shared in a manner that will involve you saying this is

383	my blood which contains something that I don't want anyone to know and is it going
384	to be shared in that manner? If it is going to be shared without my identity that
385	shouldn't be a problem.' (CAB member, Accra).
386	I think if he would share it with another person, he has to seek my consent before
387	he could share it with another person. If not, he is exposing my secret to someone
388	else (Stoke caregiver, Kumasi).
389	On the other hand, there was a participant who was not too concerned about the privacy
390	and confidentiality of data,
391	I don't have a problem with it. I gave it out so that it can be used to help others so
392	I am okay with it being shared (Stroke survivor, Kumasi).
393	
394	Data security
395	A relatively large number of participants expressed concerns about the security of data obtained
396	from bio-sample data from participation in stroke genomic and neurobiobanking research
397	The issue of confidentiality is very important because if data is not properly
398	managed there could be leakage which has legal implications that may result in
399	suing ourselves (Stroke survivor, Abeokuta).
400	Stigmatization

401 Most participants acknowledged the risk associated with stroke genomic and neurobiobanking
402 research. A potential risk is stigmatization.

403 *I think that stigmatization is also another factor, and we are in a society where*

404 people would always be stigmatized and given names based on their sickness and

405 because of this people find it very difficult opening up, to give themselves up for a

406

certain research work... (Stroke survivor, Accra).

These views suggest that an individual's health condition, especially when it is stigmatized, may influence response to persons experiencing or who had experienced one form of ill-health condition would want to participate in research on such condition or not.

410

411 **Discussion**

The study explored participants' perception of ethical issues in genomics and neurobiobanking using the Beauchamp and Childress (2001) ethical principles of autonomy, beneficence and nonmaleficent. Data revealed similar sensitivities in perception from participants that understanding of research purpose, disclosure of details of the research process, coercion, inducement, individual outcomes, knowledge of treatment of stroke, diagnosis of stroke genetic disorders, privacy and confidentiality, data security, and stigmatization were critical ethical concerns associated with genomic and neurobiobanking research identified by participants across the study sites.

419

Participants were of the view that understanding and participation in stroke genomic and neurobiobanking research depends on how ethical issues and concerns are taken into consideration in the research process. Participants argued that the relationship between participants and researchers is shaped by community engagement strategy resulting in how well the potential participants understand the research process starting with the informed consent, use of the sample, and data sharing in an ethically safe approach. This finding agrees with other emerging body of knowledge from Africa on the collection, use, storage, and data sharing of biological samples [14-

427 17]. Participants were of the view that adequate understanding of research during the consenting 428 process is important for making well informed decision. This confirms the view expressed in an earlier study by [18] where it was argued that comprehension of information is an important 429 430 ingredient to achieving free and informed consent decision making. Therefore, advancing research 431 endeavours and promoting willingness especially in genomics and neurobiobanking requires 432 innovative ways such as equipping researchers with adequate knowledge of the vocabularies in the field as well as translating them to the language of the participants for ease of comprehension. For 433 example, we previously developed a mini dictionary showing definitions of vocabularies present 434 435 in both our study instruments and the informed consent document [19]. This was translated to the 436 main local languages in the different sites and each research assistant used this as guide when 437 engaging the research participants in the language of their choice. This enhanced better 438 understanding of the research focus and processes among the study participants.

While most participants viewed data sharing as a benefit, privacy and confidentiality of information were major ethical concerns raised by most of the participants. These views suggest that researchers have an obligation to accord respect to participants and allow them make an autonomous decision about their preference for sharing and re-use of their data. Participants were of the view that this should be agreed upon explicitly by both participants and researchers during the informed consent process. This finding agrees with views expressed by participants in a previous study with a similar theme [16, 20].

Coercion and inducement were viewed as twin ethical issues that need to be properly addressed so that participation in genomic and neurobiobanking research would be ethical. Free and informed consent, as the process of engaging potential participants, remains the solution to avoid coercion and inducement. Similarly, majority in our previous study opined that donation for genomic

research should be a personal decision[21]. Due to the nature of genomic and neurobiobanking research, participation would be determined by how well participants are recruited and retained in the study. Coercion and inducement can be minimized by the researcher's relationship with the potential participants. When trust is established with a particular researcher it can be extended to other researchers as earlier reported [22]. It is therefore imperative that researchers be transparent with participants so that they can gain their trust. They should ensure that the trust is sustained because once trust is lost it is difficult to recapture[23].

Closely associated with trust are issues of privacy and confidentiality. This is important because they determine, to a large extent, how participants would respond to requests for use, storage and sharing of data. All these bother on how much trust research participants have towards researchers. Research participants may use potential benefits as a condition for establishing trust in the researcher as earlier reported [22]. Therefore, providing unrealistic potential benefits may cause harm to the research process. However, researchers should endeavour to discuss both short- and long-term benefits of the research with the participants[24].

Participants also raised concern about the stigmatization of health conditions as an important issue 464 465 to take into consideration during research engagement. This is because if the outcome of a diagnosis would result in a stigmatization, as is the case with stroke, participants may not want to 466 467 participate. In this study participants indicated that stigmatization is a major risk associated with stroke genomic research. Despite large scale research on the challenges associated with 468 stigmatized health conditions resulting in a large volume of scholarly publication in the literature, 469 little attention has been devoted to addressing the ethical issues on stigmatized groups and health 470 471 conditions[25]. Generally, a major ethical challenge identified with the stigmatized condition is

the vulnerability of the person experiencing it[26]. This suggests the need for researching this areato understand how better to protect the vulnerable population.

474 Conclusion

This study demonstrated that details of the research process, coercion, inducement, individual 475 476 outcomes, knowledge of treatment of stroke, diagnosis of stroke genetic disorders, privacy and 477 confidentiality, data security and stigmatization were ethical issues associated with genomic and 478 neurobiobanking research in this cohort of West African research participants. Participants were of the view that understanding and disclosure of detailed information about the research during the 479 480 consenting process would enable potential research participants make free and informed choices. Also, adequate knowledge of the research process through disclosure of information about the 481 research in the informed consent process would reduce coercion and inducement as well as 482 promote trustworthiness between participants and researchers. Participants were positive towards 483 484 participation in neurobiobanking research but have specific ethical concerns that should be addressed within local contexts. Finally, the study showed that the ethical issues around 485 stigmatizing health conditions are a major hindrance to a willingness to participate in research by 486 487 persons experiencing such stigmatizing health conditions.

488 Researchers should take into consideration the ethical concerns of stroke genomic and 489 neurobiobanking research participants in order to gain their trust and sustain their participation. 490 The researcher should also ensure that participants are fully informed about what they need to 491 know about the use, re-use, and sharing of their data and/or biological samples.

492 Funding

493 ROA is supported by the African Neurobiobank for Precision Stroke Medicine ELSI Project (U01HG010273), Recruitment and Retention for Alzheimer's Disease Diversity Genetic Cohorts 494 in the ADSP (READD-ADSP) (U19AG074865), and the Origins of Alzheimers Disease in African 495 Americans (R01AG072547) from the National Institutes of Health. MO is supported by grants 496 from the National institute of Health, the SIREN Study (U54HG007479) and the Systematic 497 Investigation of Blacks with Stroke using Genomics (SIBS Genomics) Study (R01NS107900). 498 ROA is further supported by the UK Royal Society/African Academy of Sciences 499 (FLR/R1/191813, FCG/R1/201034) and the Alzheimer Association (GBHI ALZ UK-21-24204). 500

501 **Disclosure of interest**

502 The authors report there are no competing interests to declare.

503 **References**

Mulder N, Abimiku A, Adebamowo SN, de Vries J, Matimba A, Olowoyo P, et al.
 H3Africa: current perspectives. Pharmgenomics Pers Med. 2018;11:59-66.

Rotimi C, Abayomi A, Abimiku A, Adabayeri VM, Adebamowo C, Adebiyi E, et al.
 Research capacity. Enabling the genomic revolution in Africa. Science. 2014;344(6190):1346-8.

3. H3Africa Ethics Working Group. Ethics and governance framework for best practice in
genomic research and biobanking in Africa. 2018.

Akinyemi RO, Jenkins C, Nichols M, Singh A, Wahab K, Akpalu A, et al. Unraveling the
 Ethical, Legal, and Social Implications of Neurobiobanking and Stroke Genomic Research in
 Africa: A Study Protocol of the African Neurobiobank for Precision Stroke Medicine ELSI
 Project. Int J Qual Methods. 2020;19.

5. De Vries J, Bull SJ, Doumbo O, Ibrahim M, Mercereau-Puijalon O, Kwiatkowski D, et al.
515 Ethical issues in human genomics research in developing countries. BMC medical ethics.
516 2011;12:1-10.

517 6. Joly Y, Dalpé G, So D, Birko S. Fair shares and sharing fairly: a survey of public views on
518 open science, informed consent and participatory research in biobanking. PloS one.
519 2015;10(7):e0129893.

520 7. Freund M, Taylor A, Ng C, Little AR. The NIH NeuroBioBank: creating opportunities for
521 human brain research. Handbook of Clinical Neurology. 150: Elsevier; 2018. p. 41-8.

Akinyemi R, Ojagbemi A, Akinyemi J, Salami A, Olopade F, Farombi T, et al. Gender
 differential in inclination to donate brain for research among Nigerians: the IBADAN Brain Bank
 Project. Cell Tissue Bank. 2019;20(2):297-306.

Akinyemi RO, Salami A, Akinyemi J, Ojagbemi A, Olopade F, Coker M, et al. Brain
banking in low and middle-income countries: Raison D'etre for the Ibadan Brain Ageing, Dementia
And Neurodegeneration (IBADAN) Brain Bank Project. Brain Res Bull. 2019;145:136-41.

528 10. Ascencio-Carbajal T, Saruwatari-Zavala G, Navarro-Garcia F, Frixione E.
529 Genetic/genomic testing: defining the parameters for ethical, legal and social implications (ELSI).
530 BMC Medical Ethics. 2021;22(1):1-15.

531 11. Beauchamp TL, Childress JF. Principles of biomedical ethics: Oxford University Press,
532 USA; 2001.

533 12. Iserson KV. Principles of biomedical ethics. Emergency Medicine Clinics.
534 1999;17(2):283-306.

13. Nowell LS, Norris JM, White DE, Moules NJ. Thematic analysis: Striving to meet the
trustworthiness criteria. International journal of qualitative methods.
2017;16(1):1609406917733847.

Tindana P, Molyneux CS, Bull S, Parker M. Ethical issues in the export, storage and reuse
of human biological samples in biomedical research: perspectives of key stakeholders in Ghana
and Kenya. BMC Medical Ethics. 2014;15(1):1-11.

541 15. Bukini D, Mbekenga C, Nkya S, Purvis L, McCurdy S, Parker M, et al. A qualitative study
542 on aspects of consent for genomic research in communities with low literacy. BMC medical ethics.
543 2020;21(1):1-7.

Matandika L, Ngóngóla RT, Mita K, Manda-Taylor L, Gooding K, Mwale D, et al. A
qualitative study exploring stakeholder perspectives on the use of biological samples for future
unspecified research in Malawi. BMC medical ethics. 2020;21(1):1-10.

547 17. Ochieng J, Kwagala B, Barugahare J, Mwaka E, Ekusai-Sebatta D, Ali J, et al. Perspectives
548 and ethical considerations for return of genetics and genomics research results: a qualitative study
549 of genomics researchers in Uganda. BMC medical ethics. 2021;22:1-9.

18. Jegede AS. Understanding informed consent for participation in international health
research. Developing world bioethics. 2009;9(2):81-7.

Uvere EO, Nichols M, Ojebuyi BR, Isah SY, Calys-Tagoe B, Jenkins C, et al. CapacityBuilding for Stroke Genomic Research Data Collection: The African Neurobiobank Ethical, Legal,
and Social Implications Project Experience. Biopreserv Biobank. 2023;21(2):158-65.

555 20. Erdmann A, Rehmann-Sutter C, Bozzaro C. Patients' and professionals' views related to 556 ethical issues in precision medicine: a mixed research synthesis. BMC medical ethics. 557 2021;22(1):116.

Singh A, Arulogun O, Akinyemi J, Nichols M, Calys-Tagoe B, Ojebuyi B, et al. Biological
sample donation and informed consent for neurobiobanking: Evidence from a community survey
in Ghana and Nigeria. PLoS One. 2022;17(8):e0267705.

561 22. Berrios C, James CA, Raraigh K, Bollinger J, Murray B, Tichnell C, et al. Enrolling 562 genomics research participants through a clinical setting: the impact of existing clinical 563 relationships on informed consent and expectations for return of research results. Journal of genetic 564 counseling. 2018;27:263-73.

565 23. Jegede AS. What led to the Nigerian boycott of the polio vaccination campaign? PLoS
566 medicine. 2007;4(3):e73.

567 24. Bedeker A, Nichols M, Allie T, Tamuhla T, van Heusden P, Olorunsogbon O, et al. A
568 framework for the promotion of ethical benefit sharing in health research. BMJ Glob Health.
569 2022;7(2).

570 25. Millum J, Campbell M, Luna F, Malekzadeh A, Karim QA. Ethical challenges in global
571 health-related stigma research. BMC medicine. 2019;17:1-9.

572 26. Tekola F, Bull S, Farsides B, Newport MJ, Adeyemo A, Rotimi CN, et al. Impact of social
573 stigma on the process of obtaining informed consent for genetic research on podoconiosis: a
574 qualitative study. BMC medical ethics. 2009;10:1-10.

575 Supplementary information

576 S1 File. Focus group discussion guide.